Lexaria Bioscience Corp. Discusses the Significance of Their Intellectual Property with The Stock Day Podcast
10:18 am ET November 17, 2020
Company's first patent in Europe, which was announced on October 21st, 2020. "That was patent #18 overall," shared Bunka. "We have patents granted now in both America and Australia," he added. "In Australia, about a year ago, we received a patent that allowed us to use the technology with CBD to treat heart disease," said Bunka. "Just a few weeks ago, we received a similar but broader and more important patent for Europe," he shared, adding that this patent will allow the Company to use DehydraTECHT with CBD, as well as other substances, to treat conditions like heart disease, alzheimer's, schizophrenia, and Parkinson's disease.
"We've already filed the paperwork to repeat that patent in America," said Bunka. "That really starts to change our company into a pharma or biotech company, which is something we're trying to achieve."
Tell me about the Company's impressive projections for the fourth quarter. "We set-up a facility that can implement our technology into what we call 'buckets of powder', which contain CBD and our technology is already implemented," said Bunka. "Then we sell that bulk ingredient to other businesses, and they incorporate the powder into their final products," he said. "That business is growing by leaps and bounds," shared Bunka. "It's grown by roughly 1,000% in 12 months," he added. "Quarter-by-quarter, we're expecting multi-hundred percent growth moving forward."
"We have been informed by our corporate clients to expect that they will give us orders for calendar 2021 of well in excess of 50 million servings," said Bunka. "We're talking about really incredible growth rates for us."
To close the interview, Bunka shared the Company's stock is currently near an all-time low for the last several years, making it a valuable consideration for investors. He also shared that the Company has continued to increase their intellectual property, and is currently conducting research in the antiviral sector while also moving forward with their nicotine division. "The markets that we're looking at are worth tens of billions of dollars each," explained Bunka. "We're not like a lot of companies our size because we partner with Fortune 500 companies and have demonstrated our ability," he said, adding that the Company also plans to uplist in the near future. "There are lots of catalysts coming here that should produce more value for our shareholders."
https://audioboom.com/posts/7731886-lexaria-b...-the-stock.
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/.
Kgem
2
